[go: up one dir, main page]

MX2021015188A - Moduladores de nueva generacion del estimulador de genes de interferon (sting). - Google Patents

Moduladores de nueva generacion del estimulador de genes de interferon (sting).

Info

Publication number
MX2021015188A
MX2021015188A MX2021015188A MX2021015188A MX2021015188A MX 2021015188 A MX2021015188 A MX 2021015188A MX 2021015188 A MX2021015188 A MX 2021015188A MX 2021015188 A MX2021015188 A MX 2021015188A MX 2021015188 A MX2021015188 A MX 2021015188A
Authority
MX
Mexico
Prior art keywords
sting
stimulator
interferon genes
modulators
compounds
Prior art date
Application number
MX2021015188A
Other languages
English (en)
Inventor
Charles-Henry Fabritius
Grzegorz Witold Topolnicki
Magdalena Izabela Zawadzka
Luigi Piero Stasi
Maciej Krzysztof Rogacki
Grzegorz Wojciech Cwiertnia
Lukasz Piotr Dudek
Monika Patrycja Dobrzanska
Agnieszka Justyna Gibas
Anna Rajda
Sylwia Sudol
Karolina Maria Gluza
Original Assignee
Ryvu Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ryvu Therapeutics S A filed Critical Ryvu Therapeutics S A
Publication of MX2021015188A publication Critical patent/MX2021015188A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I) y sales, estereoisómeros, tautómeros o N-óxidos de los mismos que son útiles como moduladores de STING (Estimulador de genes de interferón). La presente invención se refiere además a los compuestos de la fórmula (I) para su uso como medicamento y a una composición farmacéutica que comprende dichos compuestos.
MX2021015188A 2019-06-12 2020-06-12 Moduladores de nueva generacion del estimulador de genes de interferon (sting). MX2021015188A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19460034 2019-06-12
EP19460067 2019-12-11
PCT/EP2020/066370 WO2020249773A1 (en) 2019-06-12 2020-06-12 Next-generation modulators of stimulator of interferon genes (sting)

Publications (1)

Publication Number Publication Date
MX2021015188A true MX2021015188A (es) 2022-01-18

Family

ID=71120145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015188A MX2021015188A (es) 2019-06-12 2020-06-12 Moduladores de nueva generacion del estimulador de genes de interferon (sting).

Country Status (12)

Country Link
US (2) US12344606B2 (es)
EP (1) EP3983078B1 (es)
JP (1) JP7110503B2 (es)
KR (1) KR102812984B1 (es)
AU (1) AU2020291796B2 (es)
BR (1) BR112021024948A2 (es)
CA (1) CA3140257C (es)
ES (1) ES2972507T3 (es)
IL (1) IL288868B2 (es)
MX (1) MX2021015188A (es)
PL (1) PL3983078T3 (es)
WO (1) WO2020249773A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7664680B2 (ja) 2017-03-29 2025-04-18 リガケム バイオサイエンシズ， インク． ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物
WO2019238786A1 (en) 2018-06-12 2019-12-19 Ryvu Therapeutics S.A. Modulators of stimulator of interferon genes (sting)
CN113950473B (zh) * 2019-06-12 2025-07-22 雷沃医疗有限公司 干扰素基因刺激物(sting)的下一代调节剂
AU2020401358B2 (en) * 2019-12-11 2024-02-15 Ryvu Therapeutics S.A. Functionalized heterocyclic compounds as modulators of Stimulator of Interferon Genes (STING)
JP7426486B2 (ja) * 2019-12-11 2024-02-01 ライブ・セラピューティクス・スプウカ・アクツィーナ インターフェロン遺伝子刺激因子（ｓｔｉｎｇ）のモジュレーターとしての複素環式化合物
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
WO2022045110A1 (ja) * 2020-08-24 2022-03-03 Dic株式会社 １倍体単細胞性紅藻の製造方法、及び１倍体単細胞性紅藻用培地
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3410851A (en) 1963-09-03 1968-11-12 Miles Lab Derivatives of flavone
GB0225833D0 (en) 2002-11-06 2002-12-11 Univ Leeds Nucleic acid ligands and uses therefor
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
CA2650954C (en) 2006-05-10 2014-02-11 Novartis Ag Bicyclic derivatives as cetp inhibitors
WO2010056564A1 (en) 2008-11-13 2010-05-20 Merck Sharp & Dohme Corp. Quinolone neuropeptide s receptor antagonists
PE20200696A1 (es) 2017-06-22 2020-06-16 Curadev Pharma Ltd Moduladores de moleculas pequenas de sting humana
GB2563642A (en) * 2017-06-22 2018-12-26 Curadev Pharma Ltd Small molecule modulators of human STING
US20200138827A1 (en) 2017-06-22 2020-05-07 Curadev Pharma Limited Small molecule modulators of human sting
JP7274478B2 (ja) 2017-07-27 2023-05-16 スティングレイ・セラピューティクス・インコーポレイテッド 置換された－３Ｈ－イミダゾ［４，５－ｃ］ピリジン及び１Ｈ－ピロロ［２，３－ｃ］ピリジンシリーズの新規なエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ－１（ＥＮＰＰ１）並びにがん免疫治療薬としてのインターフェロン遺伝子（ＳＴＩＮＧ）モジュレータのための刺激剤
BR112020009592A2 (pt) 2017-11-20 2020-11-03 Silicon Swat, Inc. derivados de ácido oxoacridinil acético e métodos de uso
EP3768266A4 (en) 2018-03-20 2021-12-22 Merck Sharp & Dohme Corp. OXO-TETRAHYDRO-ISOCHINOLINE-CARBOXYLIC ACIDS AS STING INHIBITORS
WO2019238786A1 (en) 2018-06-12 2019-12-19 Ryvu Therapeutics S.A. Modulators of stimulator of interferon genes (sting)
AU2020401358B2 (en) * 2019-12-11 2024-02-15 Ryvu Therapeutics S.A. Functionalized heterocyclic compounds as modulators of Stimulator of Interferon Genes (STING)
JP7426486B2 (ja) * 2019-12-11 2024-02-01 ライブ・セラピューティクス・スプウカ・アクツィーナ インターフェロン遺伝子刺激因子（ｓｔｉｎｇ）のモジュレーターとしての複素環式化合物

Also Published As

Publication number Publication date
JP7110503B2 (ja) 2022-08-01
US12344606B2 (en) 2025-07-01
US20250313561A1 (en) 2025-10-09
EP3983078B1 (en) 2023-11-15
KR20220024467A (ko) 2022-03-03
BR112021024948A2 (pt) 2022-01-25
CA3140257A1 (en) 2020-12-17
AU2020291796A1 (en) 2021-12-16
JP2022527679A (ja) 2022-06-02
IL288868B1 (en) 2024-10-01
EP3983078A1 (en) 2022-04-20
WO2020249773A1 (en) 2020-12-17
CA3140257C (en) 2023-11-28
US20220251082A1 (en) 2022-08-11
AU2020291796B2 (en) 2024-01-18
IL288868A (en) 2022-02-01
ES2972507T3 (es) 2024-06-13
PL3983078T3 (pl) 2024-07-01
IL288868B2 (en) 2025-02-01
EP3983078C0 (en) 2023-11-15
KR102812984B1 (ko) 2025-05-26

Similar Documents

Publication Publication Date Title
MX2021015188A (es) Moduladores de nueva generacion del estimulador de genes de interferon (sting).
MX2022007178A (es) Compuestos heterociclicos como moduladores del estimulador de genes de interferon (sting).
CR20220126A (es) Moduladores de sting (estimulador de genes de interferón)
CR20200312A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
ECSP15008851A (es) Compuestos heteroaromáticos como inhibidores de btk
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112018077015A2 (pt) derivados de ácido borônico e usos terapêuticos dos mesmos
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CR20190504A (es) COMPUESTO DE AMIDA (Divisional 2015-0454)
CO6852096A2 (es) Métodos plaguicidasque utilizan compuestos de 3-piridil tiazol sustituidos y derivados para combatir las plagas de animales i
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
CL2020002352A1 (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CU20170026A7 (es) Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
MX393586B (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
CO2018007136A2 (es) Derivados de heterocicleno como agentes de control de plagas
CO2019013823A2 (es) Compuestos heteroaromáticos como inhibidores de vanina
ECSP17069696A (es) Compuestos novedosos
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
UY37556A (es) Derivados heterocíclicos como pesticidas
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.